{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"DOR great than 6 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"DOR great than 12 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"DOR great than 18 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"DOR was calculated for subjects with a confirmed CR or PR. DOR is defined as the time from the date of the initial response (CR/PR) to the date of first documented PD or death due to any cause, whichever occurs first.\n\nDOR censoring rules followed those of the PFS analysis defined in the SAP. DOR was analyzed using the Kaplan-Meier methods and the median DOR, first quartile, and third quartile was presented. The associated 2- sided 95% CIs was estimated.","groups":[{"description":"Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 statu","id":"OG000","title":"Part 1"},{"description":"Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma","id":"OG001","title":"Part 2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Every 6 weeks up to disease progression or start of new anti-cancer therapy assessed for up to 12 months","title":"Part 1 and 2: To Evaluate the Duration of Response (DOR) in Subjects With Confirmed CR or PR","type":"SECONDARY","unitOfMeasure":"Participants"}